Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: a meta-analysis of randomized trials

Figures & data

Figure 1. PRISMA flowchart.

Figure 2. Overall quality assessment of included studies.

Table 1. Baseline characteristics of the included studies. 

Author	year	country	Inclusion criteria	Target of intensive therapy	Target of standard therapy	Age	Male, n%	Mean follow-up time
Deng	2023	China	Patient age 60–80 years	SBP < 110–130mmHg	SBP < 130–150mmHg	66.1 ± 4.8 vs 66.2 ± 4.8	46.7% vs 46%	3.24Y
Soliman	2015	The US and Canada	Patients with T2DM at high risk of CVD	SBP < 120 mm Hg	SBP < 140 mm Hg	62.1 ± 6.7 vs 62.2 ± 6.9	46.8% vs 47.3%	4.4Y
Soliman	2017	The US	Patients without T2DM at a risk of CVD	SBP < 120 mm Hg	SBP < 140 mm Hg	67.9 ± 9.2 vs 67.8 ± 9.3	64.4% vs 65.1%	3.81Y
Reboldi	2013	Italy	Patients with CVD	SBP < 130 mm Hg	SBP < 140 mm Hg	71.7 ± 7.6 vs 66 ± 6.8	46.6% vs 57.4%	2Y
Reboldi	2013	Italy	Patients without CVD	SBP < 130 mm Hg	SBP < 140 mm Hg	66 ± 6.8 vs 66 ± 7.3	39.9% vs 37.7%	2Y

T2DM: Type 2 Diabetes Mellitus; CVD: cardiovascular diseases.

Table 2. Occurrence/regressive of LVH in the included studies. 

Author	Year	Total sample size intensive /standard group		Sample size without LVH intensive /standard group		Sample size with LVH intensive /standard group
		Events/Participants		Events/Participants		Events/Participants
Deng	2023	575/3578	633/3563	305/2985	403/2975	270/593	230/588
Soliman	2015	99/2154	120/2177	35/2039	62/1997	64/115	58/118 166/303
Soliman	2017	329/4086	372/4078	118/3784	206/3775	211/302
Reboldi	2013	4/101	16/115
Reboldi	2013	25/457	42/438

LVH: left ventricular hypertrophy.

Figure 3. Forest plot of the occurrence of LVH (1 People at high CVD risk; 2 People at low CVD risk).

Figure 4. Forest plot of occurrence of LVH in the population without LVH at baseline.

Figure 5. Forest plot of LVH regression.